Cover Image
市場調查報告書

原發性膽汁性肝硬化(PBC) : 開發平台分析

Primary Biliary Cirrhosis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 200481
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
原發性膽汁性肝硬化(PBC) : 開發平台分析 Primary Biliary Cirrhosis - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 106 Pages
簡介

原發性膽汁型肝硬化(PBC)是肝臟的慢性疾病,因自體免疫性造成惡化性膽汁淤積,有時一直惡化到肝臟疾病末期。PBC的患者幾乎皆為女性,此外50∼60歲發病病例最多。

本報告提供全球各國治療原發性膽汁性肝硬化(以下簡稱PBC)用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

原發性膽汁性肝硬化(PBC)概要

治療藥的開發

  • PBC開發中產品:概要
  • PBC開發中產品:比較分析

各企業開發中的PBC治療藥

大學/研究機關研究中的PBC治療藥

開發中產品的概要

  • 最後階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

PBC治療藥:開發中的產品一覽(各企業)

PBC開發治療藥的企業

  • AlbireoPharma
  • CymaBay Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Enanta Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Intercept Pharmaceuticals, Inc.
  • Johnson & Johnson
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Virobay Inc.

原發性膽汁性肝硬化(PBC):治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • A-4250
  • budesonide
  • FFP-104
  • GSK-2330672
  • MBX-8025
  • NGM-282
  • obeticholic acid
  • RhuDex
  • Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis
  • ustekinumab
  • VBY-825

PBC治療藥:最新的藥物簡介

PBC相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9522IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 1, 11, 5, 1 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Biliary Cirrhosis - Overview
    • Primary Biliary Cirrhosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Primary Biliary Cirrhosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
    • Albireo Pharma Inc
    • Arena Pharmaceuticals Inc
    • CymaBay Therapeutics Inc
    • Eisai Co Ltd
    • Enanta Pharmaceuticals Inc
    • Genfit SA
    • GenKyoTex SA
    • Gilead Sciences Inc
    • GlaxoSmithKline Plc
    • Intercept Pharmaceuticals Inc
    • MediGene AG
    • NGM Biopharmaceuticals Inc
    • Novartis AG
    • Retrophin Inc
    • Shire Plc
    • Tiziana Life Sciences Plc
    • Virobay Inc
    • Zydus Cadila Healthcare Ltd
  • Primary Biliary Cirrhosis - Drug Profiles
    • A-4250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-6011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDP-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elafibranor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etrasimod arginine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FFP-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • foralumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GKT-831 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-9674 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2330672 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJN-452 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • maralixibat chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RhuDex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saroglitazar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seladelpar lysine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ursodiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Biliary Cirrhosis - Dormant Projects
  • Primary Biliary Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
      • May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis
      • Apr 19, 2017: Intercept Announces New Ocaliva (obeticholic acid) and INT-767 Data to be Presented at EASL 2017
      • Apr 05, 2017: Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2017
      • Feb 23, 2017: Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis
      • Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
      • Oct 20, 2016: CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting
      • Oct 20, 2016: CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines Designation for the Treatment of Primary Biliary Cholangitis
      • Oct 05, 2016: CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis
      • Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC
      • May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
      • May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC
      • May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
      • Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL
      • Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Primary Biliary Cirrhosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Genfit SA, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by MediGene AG, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Novartis AG, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Shire Plc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Tiziana Life Sciences Plc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H2 2017
  • Primary Biliary Cirrhosis - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017
  • Primary Biliary Cirrhosis - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Primary Biliary Cirrhosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top